Skip to content
MARKETS / NYSE / MED
NYSE · MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS · MID CAP

Medifast Inc. MED

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$385.8M
▼ 36.0% YoY
$-18.7M
▼ 993.0% YoY
$1.2M
▼ 92.7% YoY
In brief

What this company does

Medifast develops and markets products for consumers who want to lose weight and adopt a holistic approach to overall health and wellness. Its coaches are independent contractors, not employees, who support clients and market its products and services to friends, family and other people in their communities, primarily through word-of-mouth, email and social media channels. For the quarter ended December 31, 2025, the company had a network of approximately 16,100 active earning independent coaches. As of December 31, 2025, it employed 380 team members, all in the United States, of whom 173 were engaged in manufacturing, logistics and supply chain support, and 207 in marketing, administrative and corporate support functions. No single customer accounted for 10% or more of its consolidated revenue for the year ended December 31, 2025. Operations are conducted through the wholly owned subsidiaries Jason Pharmaceuticals, Inc., OPTAVIA LLC, Jason Enterprises, Inc., Jason Properties, LLC, OPTAVIA (Hong Kong) Limited, and OPTAVIA Health Consultation (Shanghai) Co., Ltd. Jason Pharmaceuticals, Inc., a wholly-owned subsidiary with a manufacturing facility in Owings Mills, Maryland, manufactures the company's products and accounts for approximately 40% of total unit sales. The products underlying the remaining 60% of total unit sales are manufactured by co-manufacturers in accordance with Medifast proprietary formulas and manufacturing standards.

Written from the business description in Medifast, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 17 February 2026. Every sentence was checked against that document before publication.

Growth
USD 385.8M
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.4 · Net income -0.0
0.8B200920112013201520172019202120232025
Compound annual growth
−37.7%
−16.2%
+3.5%
+2.7%
−90.1%
−67.8%
−32.9%
+12.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −16.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−5 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -3.7% · Net -4.8%
5%10%-2%-4%200920112013201520172019202120232025
ROE
FY2025 · ROE -9.1%
50%200920112013201520172019202120232025

Each USD of equity lost 9 cents this year.

Cash & shareholders
USD 195,000.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 1.2
80M160M200920112013201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends 0.2 · Net buybacks 0.0
80M160MDividendsNet buybacks200920112013201520172019202120232025

USD 195,000.00 in dividends went back to shareholders in a year without profit.

Total assetsUSD 248.0M
EquityUSD 198.9M
CashUSD 89.3M
Current ratio4.69×

Equity funds 80% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.40.61.11.61.50.90.70.50.30.30.30.30.30.30.30.30.2
Operating income $B−0.00.00.10.20.20.10.10.10.00.00.00.00.00.00.00.00.0
EBITDA $B0.00.00.10.20.20.10.10.10.00.00.00.00.00.00.00.0·
Income tax $B0.00.00.00.00.10.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B−0.00.00.10.10.20.10.10.10.00.00.00.00.00.00.00.00.0
Free cash flow $B0.00.00.10.20.10.10.10.10.00.00.00.00.00.00.00.00.0
EPS, diluted $−1.700.199.1012.7313.898.686.434.622.291.491.661.031.731.161.311.350.77
Dividend / sh $0.000.004.956.565.684.523.382.191.441.070.250.000.00····
Payout %−1347350395245425667·······
ROE %−9.11.055.880.391.278.572.851.727.419.323.714.725.319.325.532.723.8
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMiscellaneous Food Preparations & Kindred Products
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image